abstract BACKGROUND AND OBJECTIVES: There is evidence that new methods of noninvasive ventilation (NIV) support have significantly changed respiratory distress syndrome (RDS) management in preterm infants. Further perspectives for neonatologists involve the assessment of different NIV strategies in terms of availability, effectiveness, and failure. This study evaluates the efficacy of 2 different NIV strategies for RDS treatment in very low birth weight (VLBW) infants: nasal synchronized intermittent positive pressure ventilation (NSIPPV), which is a modality of conventional ventilation with intermittent peak inspiratory pressure, and bilevel continuous positive airway pressure (BiPAP), not synchronized, with 2 alternate levels of continuous positive airway pressure.
WHAT'S KNOWN ON THIS SUBJECT: Noninvasive ventilation (NIV) reduced the need of intubation in preterm infants with RDS. However, randomized studies comparing nasal synchronized intermittent positive pressure ventilation and bilevel continuous positive airway pressure are still lacking.
WHAT THIS STUDY ADDS:
The present study shows no differences in short-term outcomes between 2 different NIV strategies, nasal synchronized intermittent positive pressure ventilation and bilevel continuous positive airway pressure, in preterm infants for the initial treatment of RDS. In recent decades, considerable changes have been made in the management of respiratory distress syndrome (RDS), supporting the notion that appropriate perinatal management can be effective by minimizing the use of mechanical ventilation (MV) in very low birth weight (VLBW) infants. In particular, antenatal steroid prophylaxis, accurate delivery room and respiratory management with early nasal continuous positive airway pressure (NCPAP), surfactant replacement in the early phase of RDS, the INSURE (intubation, surfactant extubation) procedure, and the increased use of noninvasive ventilation (NIV) have been shown to improve respiratory outcome. [1] [2] [3] [4] [5] The hypothetical advantages of NIV, compared with invasive MV, consist in the possibility to reduce barotrauma, biotrauma, and ventilator-induced lung injury. Data on NIV support, such as nasal intermittent positive pressure ventilation (NIPPV), nasal synchronized intermittent positive pressure ventilation (NSIPPV), and bilevel continuous positive airway pressure (BiPAP), are still controversial. On the one hand, NSIPPV/NIPPV has shown promising short-and long-term respiratory outcomes compared with NCPAP or MV. [6] [7] [8] [9] [10] On the other hand, Kirpalani et al found no significant differences between NCPAP and NIV strategies (ie, NSIPPV/NIPPV/BiPAP) in a wider study population, in terms of mortality or occurrence of bronchopulmonary dysplasia (BPD). 11 In this regard, Roberts et al described several discrepancies among studies previously conducted (ie, recruited populations, ventilation modalities, devices used, synchronization systems, and clinical applications) and concluded that, at this stage, no clear advantages were detectable for NIPPV or BiPAP over NCPAP in reducing mortality or BPD. 12 Moreover, no studies elucidating any differences between NSIPPV and BiPAP, used as the primary mode of ventilation for RDS, are yet available, except for a nonrandomized study. 13 Therefore, the present randomized study aimed to investigate the effectiveness of these 2 different NIV strategies: NSIPPV, synchronized with an intermittent positive pressure, and BiPAP, nonsynchronized with 2 alternate levels of continuous positive airway pressure (CPAP), as the primary mode of ventilation in the respiratory management of RDS in VLBW infants in terms of duration and failure of NIV support and of selected secondary outcomes.
METHODS
We conducted a randomized study in 124 VLBW infants, admitted in 2 NICUs (C. Arrigo, Children's Hospital, Alessandria, Italy, and V. Buzzi, Children's Hospital, Milan, Italy) from January 2010 to December 2012, delivered before 32 weeks of gestational age (wGA) with a birth weight ,1500 g (Fig 1) . Approval was obtained from the respective local ethics committees. Informed and written consent was obtained, before delivery, from all parents of the patients before inclusion in the study.
The protocol for delivery room management, RDS treatment, devices and interfaces used, and ventilator adjustment were the same for the 2 centers. Infants who had signs of RDS at birth were treated with sustained lung inflation (SLI) 14 and NCPAP in addition to the American Academy of Pediatrics recommendations. 15 The respiratory strategy for RDS treatment in the newborns was as follows. In the delivery room, after oropharyngeal and nasal suctioning, pressure-controlled SLI (25 cmH 2 O) was performed for 15 seconds using a neonatal mask and a T-piece ventilator (Neopuff Infant T-Piece Resuscitator, Fisher & Paykel, Auckland, New Zealand), followed by the delivery of 5 cmH 2 O NCPAP. 16 The SLI maneuver was repeated in patients in whom respiratory and/or heart failure persisted. After failure of the second SLI maneuver, infants were intubated. In both groups, neonatal care was started at the lowest oxygen concentration, between 0.21 and 0.4 fraction of inspired oxygen (FIO 2 ), to maintain arterial oxygen saturation (SaO 2 ) of 85% to 93%. All enrolled infants were transferred to the NICU with NCPAP support (5 cmH 2 O). Further support depended on gestational age (GA):
FIGURE 1
Flow chart describing recruitment. 
Surfactant Administration
According to the protocol of respiratory management, the first dose of surfactant was administered at 200 mg/kg (Curosurf, Chiesi, Parma, Italy). Additional doses of surfactant were given at 100 mg/kg, at least 12 hours after previous administration. After INSURE, newborns received the same NIV support device as before.
All newborns were treated with caffeine (caffeine citrate 20 mg/kg loading dose; 5 to 10 mg/kg/day maintenance).
Monitoring Parameters
Newborns were monitored by using pre-postductal SaO 2 monitoring (Masimo Datascope Radical, Masimo Corporation, Irvine, CA). For each infant, the following variables were recorded: GA, BW, gender, main maternal pregnancy diseases, mode of delivery, and Apgar scores at 1 to 5 minutes. At study entry, FIO 2 , mean airway pressure (MAP), SaO 2 , pH, and PCO 2 were recorded.
Primary Outcomes
The primary end points were the duration of NIV support and failure rate. 
Secondary Outcomes

Statistical Analysis
For the calculation of sample size, we used duration of ventilation as the main primary outcome. As no basic data are available for this high-risk population, we were able to retrieve the duration of ventilation by the 2 different NIV strategies from the database of our 2 NICUs. These data were used for the power calculation. We assumed a difference of 24 hours between the 2 groups in the duration of NIV as clinically relevant. At a confidence level a = 0.05 and power level of 0.80, we needed 62 patients for each group. 22 The sample size was calculated by using nQuery Advisor (Statistical Solutions, Saugus, MA), version 5.0.
Data were reported as means and SD and median and interquartile ranges for continuous variables, whereas absolute and relative frequencies were used for categorical variables.
Parameters of the 2 groups were compared using Student t or MannWhitney U 2-sided tests for continuous variables and x 2 or Fisher exact test for categorical variables. P ,.05 was considered statistically significant, and all P values were based on 2-tailed tests. Statistical analysis was performed by using SPSS for Windows (SPSS, Chicago, IL). Table 1 shows the perinatal characteristics in the studied groups. No significant differences (P . .05) were found between NSIPPV and BiPAP groups for wGA, BW, gender, incidence of cesarean delivery, premature rupture of membranes, evidence of chorioamnionitis, occurrence of pregnancy hypertension requiring antihypertensive agent treatment, abruptio placentae, occurrence of multiple pregnancies, complete course of prenatal glucocorticoids prophylaxis, and Apgar scores at 1 and 5 min. No differences were shown regarding blood gas analysis, FIO 2 , SaO 2 , pH, and PCO 2 at study entry. We observed a significant difference in MAP that was higher in the NSIPPV group than the BiPAP group, depending on the initial ventilator settings. Table 2 shows primary and secondary outcome characteristics. No significant differences were found between groups in terms of duration of ventilation on NIV support and incidence of failure. Moreover, there were no significant differences in the incidence of postnatal death, moderate/severe BPD, PNX, IVH, PVL, postnatal glucocorticoid administration, multiple surfactant doses, PDA, ROP, NEC, LOS, or time to regain BW. PNX occurred in 6 cases (NSIPPV, n = 2; BiPAP, n = 4) and represented a cause of NIV failure in 3 cases (NSIPPV, n = 2; BiPAP, n = 1).
RESULTS
In 18 of 124 infants (NSIPPV, n = 10; BiPAP, n = 8), NIV support failed. The causes were early-onset sepsis (NSIPPV, n = 5; BiPAP, n = 3), pulmonary hypertension (NSIPPV, n = 5; BiPAP, n = 4), hypoxia and hypercapnia (NSIPPV, n = 2; BiPAP, n = 4), hypoxia alone (NSIPPV, n = 3; BiPAP, n = 3), PDA (NSIPPV, n = 1), NEC (BiPAP, n = 2), and PNX (NSIPPV, n = 2; BiPAP, n = 1). Data are presented as the mean 6 SD or n.
hours [19 to 65]) (P . .05) ( Table 3) .
We did not find statistically significant differences in the incidence of failure either between the 2 study groups (P . .05 for all) or between failure subgroups after stratification for wGA (Table 3 ). In addition, infants who failed did not significantly differ in baseline characteristics from infants who did not fail on NIV.
DISCUSSION
In the last decade, new therapeutic strategies and technological advances have considerably changed RDS treatment in VLBW infants. New delivery room management and early NIV support significantly contributed to a sensible decay in the need for MV support. [23] [24] [25] [26] [27] [28] Thus, further perspectives for neonatologists involve the assessment of different NIV strategies in terms of availability, effectiveness, and failure.
In the present 2-center randomized study, we found no differences in primary and secondary end points between 2 different NIV strategies (ie, NSIPPV and BiPAP) performed as primary modes for RDS treatment.
Results are consistent and offer additional support to a previous nonrandomized observation using NSIPPV and BiPAP as primary modes in the treatment of RDS. 13 In our series, we also found a low incidence of failure (18 of 124 newborns, 15%) and a brief time of respiratory support (median for NSIPPV 89 hours; for BiPAP 87 hours). Moreover, no correlations were found between failure occurrences and GA subgroups.
Low failure in NIV support can be also explained on the basis of perinatal treatments, such as prenatal glucocorticoid prophylaxis (85% to 90% for our population), known to be effective on lung immaturity, and improvements in delivery room management such as SLI and early NCPAP. Recent observations reported an improved postnatal adaptation, in terms of lung and cardiovascular function, in SLI-treated infants and animals. 29, 30 Another explanation can be the early NCPAP support in the delivery room, which is known to be beneficial for lung outcome. 2, [23] [24] [25] [26] [27] [28] Although the current study shows that both methods of NIV (SIPPV and BiPAP) are feasible and probably equally effective, it does not answer the question whether NIV is better than NCPAP as primary treatment of RDS. Several authors in smaller study populations (NIPPV or BiPAP versus NCPAP) and a meta-analysis reported less need of MV, less risk of intubation in the first 72 hours from birth, and reduction of hospitalization duration and O 2 dependency. 7,10,31-33 However, Kirpalani et al, in a recent large multicenter trial, showed no significant differences in terms of mortality or BPD occurrence between NCPAP and NIV strategies, used both as first intention or in the weaning phase, but without a specific protocol for NIV (devices, modalities, synchronization). 11 Finally, Roberts et al suggested that NIPPV (synchronized or nonsynchronized) might be advantageous over NCPAP as primary support for reduction of Data are presented as the median (25th to 75th centile), n, or mean 6 SD. 23 whereas a selective therapeutic strategy was planned for those .26 wGA. 44 Currently, prophylactic approaches do not seem to be justified, and further investigations to clarify the efficacy of early NIV with the best timing for surfactant administration, especially in extremely low birth weight infants, are eagerly awaited. 45 We did not find any differences between groups in the need for surfactant single/multiple doses.
In the present series, we found no statistically significant differences in secondary outcomes between the 2 NIV devices. Of course, the small number of infants eligible for statistical analysis of secondary outcomes does not allow us to draw definite conclusions. In this respect, we observed a moderate/severe BPD incidence, comparable to that of previous studies. 38, 46 The low incidence of PNX, NEC, or bowel perforations suggests that NIV techniques could be considered reasonably safe for these infants.
Last but not least, successful NIV management requires a high quality of neonatal care. High-risk infants require experienced nurses for the best cleaning of the upper airways, nasal cannula positioning, and maintaining the containment position of the newborns. These precautions are implemented to ensure effective airflow, maintaining adequate pressure from the nostrils to the distal airways, to increase comfort of the newborns and prevent trauma to the nostrils. 47 
CONCLUSIONS
The present data show that both NSIPPV and BiPAP, used as primary respiratory support in the treatment of RDS of VLBW infants, are feasible and equally effective. These results prompt further RCT investigations to evaluate the effectiveness of different NIV strategies on long-term outcomes.
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